NCT04766177View on ClinicalTrials.gov

Role of Bumetanide in Treatment of Autism

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 1, 2030

Study Completion Date

December 1, 2030

Conditions
Autism
Interventions
DRUG

Bumetanide

bumetanide 0.5 mg twice daily

DRUG

Placebo

placebo tablets twice daily

Trial Locations (1)

Unknown

RECRUITING

Sherief Abd-Elsalam, Tanta

All Listed Sponsors
lead

Sherief Abd-Elsalam

OTHER

NCT04766177 - Role of Bumetanide in Treatment of Autism | Biotech Hunter | Biotech Hunter